Telehealth providers in Illinois

Verified telehealth providers serving Illinois

Telehealth prescribing rules in Illinois

The Telehealth Act (225 ILCS 150) defines telehealth as the evaluation, diagnosis, or interpretation of electronically transmitted patient-specific data between a remote location and a licensed professional that generates interaction or treatment recommendations, lets a professional practice telehealth to the extent of the scope set by their licensing act, and requires the in-person standard of care. A professional treating a patient located in Illinois must be licensed or authorized to practice in Illinois, and section 49.5 of the Medical Practice Act (225 ILCS 60/49.5) separately requires a physician engaged in telemedicine with Illinois patients to hold an Illinois license. The statutes do not set a real-time video requirement for non-controlled prescriptions, but they also do not expressly approve questionnaire-only prescribing. Section 5 of the Telehealth Act defines telehealth services to include care delivered by an asynchronous store and forward system (transmission that does not require real-time interaction), e-visits, and virtual check-ins, so asynchronous care is a recognized telehealth modality, held to the in-person standard of care under section 15. Neither the Act nor the IDFPR pharmacy page addresses whether a first prescription may follow an asynchronous-only intake, and no IDFPR guidance on that point was found, so async_prescribing_allowed is left unknown. [1] [2] [3] [6]

Compounded GLP-1 access in Illinois

Illinois patients using telehealth GLP-1 programs should confirm the prescriber holds an Illinois license and that the dispensing pharmacy holds an IDFPR nonresident pharmacy license. IDFPR has not issued its own GLP-1 rule, but it relays federal positions to licensees: its Pharmacy page posts FDA's July 2024 letter on adverse events with compounded semaglutide and tirzepatide, and its Spring 2025 compliance newsletter restated FDA's timelines that ended 503A enforcement discretion for compounded tirzepatide and set April 22, 2025 for semaglutide. [1] [2] [4] [8] [10]

Research use only sellers in Illinois

Only IDFPR-licensed pharmacies, including licensed nonresident pharmacies, may dispense prescription drugs to Illinois patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling and are not dispensed by a pharmacist. The Illinois Food, Drug and Cosmetic Act, 410 ILCS 620/17, separately bars any person from selling, delivering, holding for sale, or giving away a new drug unless an application for it has been approved under section 505 of the federal act, and 68 Ill. Adm. Code 1330.30(j) makes dispensing a drug that is not FDA approved, not in the USP-NF, and not on the FDA bulks list unprofessional conduct for a licensee. [4] [5] [7] [11]